

Youhua Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8490612/publications.pdf>

Version: 2024-02-01

19
papers

162
citations

1307594

7
h-index

1199594

12
g-index

23
all docs

23
docs citations

23
times ranked

207
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIBâ€“IIIB resectable lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1760-1768.	1.4	36
2	Prognostic Nomogram for Thoracic Esophageal Squamous Cell Carcinoma after Radical Esophagectomy. <i>PLoS ONE</i> , 2015, 10, e0124437.	2.5	24
3	Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p. <i>Bioengineered</i> , 2021, 12, 3525-3538.	3.2	18
4	Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 50624-50634.	1.8	13
5	Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 639-647.	2.3	11
6	Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2149-2155.	2.0	10
7	The classification and treatment strategies of post-esophagectomy airway-gastric fistula. <i>Journal of Thoracic Disease</i> , 2020, 12, 3602-3610.	1.4	10
8	Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma. <i>Journal of Cancer</i> , 2020, 11, 6516-6529.	2.5	9
9	Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy. <i>Annals of Translational Medicine</i> , 2022, 10, 325-325.	1.7	9
10	Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 603671.	2.8	8
11	Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study. <i>BMC Surgery</i> , 2020, 20, 302.	1.3	7
12	The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 278-278.	1.6	5
13	The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis. <i>Iranian Journal of Public Health</i> , 2019, 48, 1265-1269.	0.5	1
14	Neoadjuvant immunotherapy for elderly patients with non-small-cell lung cancer: a case report and literature review. <i>Annals of Translational Medicine</i> , 2021, 9, 182-182.	1.7	0
15	Nomogram predicting long-term survival probability of thoracic esophageal squamous cell carcinoma after radical esophagectomy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4094-4094.	1.6	0
16	Weekly nab-paclitaxel in combination with cisplatin as neoadjuvant chemotherapy in patients (pts) with locally advanced esophageal squamous cell carcinoma (SCC): Preliminary results of a phase study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15062-e15062.	1.6	0
17	A phase II study of weekly nab-paclitaxel in combination with cisplatin as neoadjuvant chemotherapy in patients (pts) with locally advanced esophageal squamous cell carcinoma (SCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 122-122.	1.6	0
18	Neoadjuvant versus adjuvant treatment: Which one is better for resectable locally advanced esophageal squamous cell carcinoma?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4060-4060.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Chemoradiotherapy with and without surgery in patients with locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15025-e15025.	1.6	0